78725-46-9

Usage

Uses

Used in Pharmaceutical Industry:
3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE is used as a key intermediate in the synthesis of complex organic molecules for drug development. Its unique chemical structure allows for the creation of new pharmaceutical compounds with potential therapeutic applications.
Used in Chemical Industry:
3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE is used as a building block in the synthesis of various organic compounds, including dyes, pigments, and other specialty chemicals. Its versatility in chemical reactions makes it a valuable component in the development of new materials and products.
Specific Applications:
3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE is used in the synthesis of:
5,10,15,20-tetra[3-(3-trifluoromethyl)phenoxy]porphyrin: 3-[3-(TRIFLUOROMETHYL)PHENOXY]BENZALDEHYDE has potential applications in the development of new materials for solar energy conversion and photocatalysis.
4-4-naphthalen-2-yl-5-[3-(3-trifluoromethyl-phenoxy)-phenyl]-imidazol-1-yl-piperidine: This complex organic molecule may have potential applications in the pharmaceutical industry, particularly in the development of new drugs with unique therapeutic properties.

InChI:InChI=1/C14H9F3O2/c15-14(16,17)11-4-2-6-13(8-11)19-12-5-1-3-10(7-12)9-18/h1-9H

Upstream product

• 98-17-9 3-Trifluoromethylphenol 
• 87199-16-4 3-Formylphenylboronic acid 
• 24393-13-3 2'-(3-hydroxyphenyl)-[1',3']-dioxane 
• 100-83-4 meta-hydroxybenzaldehyde 

Relevant academic research and scientific papers

Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors

Mycobacterium tuberculosis thymidylate kinase (MtTMPK) has emerged as an attractive target for rational drug design. We recently investigated new families of non-nucleoside MtTMPK inhibitors in an effort to diversify MtTMPK inhibitor chemical space. We here report a new series of MtTMPK inhibitors by combining the Topliss scheme with rational drug design approaches, fueled by two co-crystal structures of MtTMPK in complex with developed inhibitors. These efforts furnished the most potent MtTMPK inhibitors in our assay, with two analogues displaying low micromolar MIC values against H37Rv Mtb. Prepared inhibitors address new sub-sites in the MtTMPK nucleotide binding pocket, thereby offering new insights into its druggability. We studied the role of efflux pumps as well as the impact of cell wall permeabilizers for selected compounds to potentially provide an explanation for the lack of correlation between potent enzyme inhibition and whole-cell activity.

Cinnamonitrile adjuvants restore susceptibility to β-lactams against methicillin-resistant staphylococcus aureus

β-Lactams are used routinely to treat Staphylococcus aureus infections. However, the emergence of methicillin-resistant S. aureus (MRSA) renders them clinically precarious. We describe a class of cinnamonitrile adjuvants that restore the activity of oxacillin (a penicillin member of the β-lactams) against MRSA. The lead adjuvants were tested against six important strains of MRSA, one vancomycin-intermediate S. aureus (VISA) strain, and one linezolid-resistant S. aureus strain. Five compounds out of 84 total compounds showed broad potentiation. At 8 μM (E)-3-(5-(3,4-dichlorobenzyl)-2-(trifluoromethoxy)phenyl)-2-(methylsulfonyl)acrylonitrile (26) potentiated oxacillin with a >4000-fold reduction of its MIC (from 256 to 0.06 mg·L-1). This class of adjuvants holds promise for reversal of the resistance phenotype of MRSA.